PATENT CLAIM ANALYSIS

Application Number: 16141849
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "275000"]

Abstract:
Methods of treating Alzheimer's disease and other neurodegenerative and/or neurocognitive and/or neurodevelopmental diseases are described. The methods comprise the administration of compounds that modulate an activity of cell division control protein 42 (Cdc42), such as the interaction between Cdc42 and intersectin (ITSN). Exemplary modulator compounds include thioureas, disulfonamides of fused aromatic systems (e.g., benzofuran), and acyl hydrazones, among others. Some of the modulator compounds act as activators of Cdc42, while others act as inhibitors. In some cases, the modulator compound has dual functionality and the ability of the modulator compound to act as an inhibitor or activator depends on whether or not Cdc42 is already activated in a particular disease stage or biological environment by an upstream activating signal of Cdc42.

Claim (Index 2):
The method of  claim 1 , wherein said modulator compound has a structure of one of Formulas (I), (II), and (III): wherein:\n Ar 1  and Ar 2  are independently selected from the group consisting of aryl, heteroaryl, substituted aryl, and substituted heteroaryl; \n A 1  and A 2  are independently selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; \n A 3  is selected from the group consisting of cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; \n A 4  is selected from the group consisting of alkoxy, aralkoxy, aryloxy, amino, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; \n X 1  is selected from the group consisting of \u2014CH\u2014, \u2014S\u2014, NR, and \u2014O\u2014, wherein R is selected from H, alkyl, and substituted alkyl; \n X 2  is O or S; \n X 3  is selected from \u2014NR 12 \u2014 and \u2014O\u2014, wherein R 12  is selected from H, alkyl, and substituted alkyl; \n X 4  is selected from NR 13  and \u2014O\u2014, wherein R 13  is selected from H, alkyl, and substituted alkyl; \n X 7  is selected from \u2014CH 2 \u2014, \u2014NH\u2014, \u2014O\u2014, and \u2014S\u2014; \n X 8  is selected from O, S, and CH 2 ; \n L 1  and L 2  are independently selected from the group consisting of alkylene, cycloalkylene, aralkylene, and arylene; \n L 3  and L 4  are each independently present or absent, and, if present are independently a \u2014(CH 2 ) n \u2014 group, wherein n is an integer between 1 and 10; \n R 14  and R 15  are independently selected from H, alkyl, and substituted alkyl; \n R 17 , R 18 , R 19 , R 20 , R 21 , and R 22  are each independently selected from the group consisting of H, halo, nitro, cyano, hydroxyl, carboxyl, acyl, alkyl, substituted alkyl, alkoxyl, aralkoxyl, aryloxyl, amino, and sulfonyl; and \n R 33  is selected from H, alkyl, and substituted alkyl; or \n a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 97.0
- Lexical Diversity: 1.57303
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14009969', '15970268', '14131655', '15554767', '14398386']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.787689497536552
- 35 USC 102 Novelty (BERT): 0.5253780499833071
- Combined Prediction Score: 0.7614583527812275
- Mean Citation Score: 318.787604
- Max Citation Score: 324.82755
- Similarity Product: 249.2751099349916

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test